A Dutch clinical stage company is developing a new generation of nanomedicines. Their aim is to use their nanoparticle technology to improve the efficacy and safety profiles of current and novel drugs for the treatment of solid tumours. As part of their development strategy, they are looking for a license and/or technical cooperation agreement with academic research labs to exploit their nanoparticles for enhanced tumour targeting of new oligonucleotides with therapeutic potential.

Description

A Dutch clinical stage company developing a new generation of nanomedicines, aims to use their proprietary nanoparticle technology to improve the efficacy and safety profiles of current and novel drugs for the treatment of solid tumours.

In humans, their platform improves the pharmacokinetics and reduces life-threatening toxicities for drugs already used in the clinic. Moreover early signs of efficacy in humans have also been observed.

As part of the company’s development plan, they are looking for collaborative opportunities to exploit their nanoparticles for enhanced tumour targeting of new oligonucleotides with therapeutic potential.

Oligonucleotides, RNA (ribonucleic acid) or DNA (deoxyribonucleic acid), are of great therapeutic potential, as they may allow to act on to date undruggable targets, as well as utilising novel and unexplored mechanisms of action.

Despite this, selective tissue targeting of oligonucleotides has been a main challenge, as when administered naked they are unstable and may trigger undesired immunogenic responses.

Effective targeting towards the appropriate intracellular compartment has also been a major hurdle thus far. These constraints have hampered the development of oligonucleotides in the clinic.

The company’s proprietary nanoparticle platform allows the entrapment of therapeutic molecules, to improve their pharmacokinetics upon intravenous (IV) or subcutaneous (SC) administration and to target them to cancer tissue where these molecules can be released extracellularly or intracellularly. The platform also offers the promise to target oligonucleotides to the applicable intracellular compartment. The client have generated initial in vivo proof of concept of enhanced oligonucleotide tumour targeting, cellular uptake, and knockdown of the target gene of interest.

To move forward the Dutch SME is looking for proprietary oligonucleotides having therapeutic potential that they can in-license and develop to the market in combination with their platform.

The therapeutic candidate needs to fit the following criteria:

  • Oligonucleotides having therapeutic potential for the treatment of solid tumours, e.g.:
  • Gene expression modulating properties: siRNA (small interfering RNA), Antisense, shRNA (short hairpin RNA), miRNA (micro RNA), TFO (triplex forming oligonucleotides), or
  • Immune stimulatory properties: CpG (C = cytosine triphosphate deoxynucleotide, p =phosphodiester link, G = guanine triphosphate deoxynucleotide), poly I:C (polyinosinic:polycytidylic acid) like oligonucleotides
  • Other applicable mechanisms

The company is looking for a license and/or technical cooperation agreement with academic research labs to exploit their nanoparticles.

Technical Specification or Expertise Sought

Biomedicine/biotechnology academic research labs with proprietary oligonucleotides with therapeutic potential for the treatment of solid tumours. Potential collaborators and their oligonucleotide should fit the following criteria:

  • Proof of concept at least in vitro but preferably in vivo in a cancer model
  • Patent protected (filed after 2013), or be patentable
  • Oligonucleotide project must be active

The Dutch company envisions a partnership in which the academic partner performs the in vitro and in vivo evaluations of the applicable oligonucleotides upon entrapment in optimized nanoparticles with the company’s input.

Type and Role of Partner Sought

The Dutch company is looking for a license agreement and/or a technical cooperation agreement with preferably an academic research lab that is open to licensing or partnering. The SME envisions a partnership in which the academic partner performs the in vitro and in vivo evaluations of the applicable oligonucleotides upon entrapment in optimized nanoparticles with the company’s input.

Los grupos de investigación que estén interesados, pueden contactar con la OTRI en la siguiente dirección: otri@uco.es Tlfno: 957-212058. Preguntar por Luis Barrón. Esta demanda caduca el 31/07/2018.